Clinical experience shows that recovery from eating disorders relies on consistent eating patterns, body acceptance, addressing weight stigma, tuning into hunger and fullness cues, and flexibility around food, but how GLP1 medications impact these recovery strategies is not well understood
How oxygen makes its presence felt
doi:10.1016/S0021-9258(19)77815-6
Like it makes me feel me personally, and I'm sure everybody reacts differently, but makes me feel calmer
With advancements in peptide research and testing, the future of peptide detection in drug tests is bright, making it easier to monitor their use while maintaining compliance with regulations
So right now, aleniglipron is actually the only oral SM GLP-1RA with disclosed Phase 2b weight loss data in the same ballpark as orforgliprons ~12.4% at 36 mg/72 wks from ATTAIN-1, with Phase 3 planned mid-2026